New Rosacea Treatment in Pipeline - Rosacea Knowledge Forum by Geoffrey Nase PhD

Dr. Geoffrey Nase · #1 (**permalink**) 1st May 2010, 11:50 AM

Paloma Pharmaceuticals, Inc throws their hat into the rosacea treatment ring with a novel dual rosacea treatment that addresses blood vessel overgrowth and rosacea skin changes (fibroplasia).

This product (P529) is already under clinical study for other inflammatory skin disorders and eye disorders. The dual mode of this treatment for rosacea offers exciting potential. Below is their clinical summary statement:

Rosacea

Rosacea is a chronic cutaneous disorder of unclear pathogenesis primarily of the convexities of the central face, often characterized by remissions and exacerbations. Rosacea produces a variety of clinical presentations grouped into four subtypes as erythematotelangiectatic, papulopustular, phymatous and ocular. Rosacea is characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The principal subtype, erythematotelangiestatic, is characterized by uncontrolled angiogenesis.

Several factors have been implicated in rosacea pathogenesis, such as climatic exposure, vasculature, dermal matrix degeneration, chemical and ingested agents, pilosebaceous unit abnormalities, genetic susceptibility, microbial organisms. Recently, much research has focused on angiogenesis as an essential process in a variety of chronic inflammatory skin diseases such as psoriasis and bullous skin diseases. Macrophages have also been implicated as contributing agents to a number of inflammatory skin disorders by promoting localized vasodilatation, angiogenesis and tissue fibrosis. Both these factors have been speculated to contribute to the pathogenesis of rosacea.

VEGF is a potent angiogenic factor, vasodilator and inflammatory agent strongly expressed by epidermal keratinocytes in many angiogenesis-dependent skin disorders. Expression of VEGF receptors, both by vascular endothelium and infiltrating mononuclear cells, is observed in rosacea. VEGF is present in epidermis and epithelium, and is expressed by infiltrating cells. VEGF receptor ligand binding may contribute to the vascular changes and cellular infiltration that occurs in rosacea. bFGF, another pro-angiogenic factor, has been implicated in rosacea.

As P529 is a potent inhibitor of angiogenesis and has been shown to inhibit both VEGF and bFGF signaling, it is the Company's feeling that P529 may provide benefit to patients with rosacea.

Please follow up on the Recent Headlines of drnase.com for an interview with the Research and Development Senior Scientist regarding the clinical rosacea studies for this treatment and the exciting potential to reverse long-standing rosacea symptoms:

Paloma Pharmaceuticals, Inc.

Dr. Geoffrey Nase · #2 (**permalink**) 4th May 2010, 07:48 PM

Quote:

Originally Posted by Dr. Geoffrey Nase

Paloma Pharmaceuticals, Inc throws their hat into the rosacea treatment ring with a novel dual rosacea treatment that addresses blood vessel overgrowth and rosacea skin changes (fibroplasia).

This product (P529) is already under clinical study for other inflammatory skin disorders and eye disorders. The dual mode of this treatment for rosacea offers exciting potential. Below is their clinical summary statement:

Rosacea

Rosacea is a chronic cutaneous disorder of unclear pathogenesis primarily of the convexities of the central face, often characterized by remissions and exacerbations. Rosacea produces a variety of clinical presentations grouped into four subtypes as erythematotelangiectatic, papulopustular, phymatous and ocular. Rosacea is characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The principal subtype, erythematotelangiestatic, is characterized by uncontrolled angiogenesis.

Several factors have been implicated in rosacea pathogenesis, such as climatic exposure, vasculature, dermal matrix degeneration, chemical and ingested agents, pilosebaceous unit abnormalities, genetic susceptibility, microbial organisms. Recently, much research has focused on angiogenesis as an essential process in a variety of chronic inflammatory skin diseases such as psoriasis and bullous skin diseases. Macrophages have also been implicated as contributing agents to a number of inflammatory skin disorders by promoting localized vasodilatation, angiogenesis and tissue fibrosis. Both these factors have been speculated to contribute to the pathogenesis of rosacea.

VEGF is a potent angiogenic factor, vasodilator and inflammatory agent strongly expressed by epidermal keratinocytes in many angiogenesis-dependent skin disorders. Expression of VEGF receptors, both by vascular endothelium and infiltrating mononuclear cells, is observed in rosacea. VEGF is present in epidermis and epithelium, and is expressed by infiltrating cells. VEGF receptor ligand binding may contribute to the vascular changes and cellular infiltration that occurs in rosacea. bFGF, another pro-angiogenic factor, has been implicated in rosacea.

As P529 is a potent inhibitor of angiogenesis and has been shown to inhibit both VEGF and bFGF signaling, it is the Company's feeling that P529 may provide benefit to patients with rosacea.

Please follow up on the Recent Headlines of drnase.com for an interview with the Research and Development Senior Scientist regarding the clinical rosacea studies for this treatment and the exciting potential to reverse long-standing rosacea symptoms:

Paloma Pharmaceuticals, Inc.

In follow up discussion with Research and development, this topical may prove beneficial to "rosacea red eye syndrome" due to its similar mechanism of action on diabetic retinopathy where fragile blood vessels break.

Admin · #3 (**permalink**) 6th May 2010, 03:28 PM

Quote:

Originally Posted by Dr. Geoffrey Nase

In follow up discussion with Research and development, this topical may prove beneficial to "rosacea red eye syndrome" due to its similar mechanism of action on diabetic retinopathy where fragile blood vessels break.

Thanks Dr. Nase. Are you publishing your interview?

Michael

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode